Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.

Hochster HS, Uboha N, Messersmith W, Gold PJ, ONeil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ.

Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23. doi: 10.1007/s00280-014-2609-3. Epub 2014 Oct 17. Erratum in: Cancer Chemother Pharmacol. 2015 Jan;75(1):25. Lenz, H-J [added].

PMID:
25322874
2.

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Rosello S, von Mehren M, Meropol NJ, Langer CJ, ONeil B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrishnan K, Galvin K, Manfredi M, Ecsedy JA.

Cancer Res. 2011 Feb 1;71(3):675-85. doi: 10.1158/0008-5472.CAN-10-1030. Epub 2010 Dec 10.

Supplemental Content

Support Center